Tarsus Pharmaceuticals, Inc. (TARS)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 1.29B |
| Enterprise value | 1.09B |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 57.95 |
| Price/book (mrq) | 6.55 |
| Enterprise value/revenue | 62.66 |
| Enterprise value/EBITDA | -8.29 |
Trading information
Stock price history
| Beta (5Y monthly) | 1.05 |
| 52-week change 3 | 137.71% |
| S&P500 52-week change 3 | 21.61% |
| 52-week high 3 | 40.40 |
| 52-week low 3 | 12.57 |
| 50-day moving average 3 | 33.62 |
| 200-day moving average 3 | 22.12 |
Share statistics
| Avg vol (3-month) 3 | 765.68k |
| Avg vol (10-day) 3 | 597.4k |
| Shares outstanding 5 | 37.5M |
| Implied shares outstanding 6 | 37.5M |
| Float 8 | 24.39M |
| % held by insiders 1 | 4.26% |
| % held by institutions 1 | 91.09% |
| Shares short (28 Mar 2024) 4 | 7.85M |
| Short ratio (28 Mar 2024) 4 | 10.57 |
| Short % of float (28 Mar 2024) 4 | 21.93% |
| Short % of shares outstanding (28 Mar 2024) 4 | 20.93% |
| Shares short (prior month 29 Feb 2024) 4 | 6.03M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | -339.94% |
Management effectiveness
| Return on assets (ttm) | -36.27% |
| Return on equity (ttm) | -69.71% |
Income statement
| Revenue (ttm) | 17.45M |
| Revenue per share (ttm) | 0.59 |
| Quarterly revenue growth (yoy) | 30.80% |
| Gross profit (ttm) | N/A |
| EBITDA | -142.28M |
| Net income avi to common (ttm) | -135.89M |
| Diluted EPS (ttm) | -4.62 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 227.44M |
| Total cash per share (mrq) | 6.65 |
| Total debt (mrq) | 31.73M |
| Total debt/equity (mrq) | 16.11% |
| Current ratio (mrq) | 6.93 |
| Book value per share (mrq) | 5.76 |
Cash flow statement
| Operating cash flow (ttm) | -117.49M |
| Levered free cash flow (ttm) | -74.48M |
© 2024 Yahoo. All rights reserved.